Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1005286 · FYE May 25 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $4.39Day +1.15%Mkt cap $165M1Y −40.1%Off 52W high −51.1%Vol (1Y) 62.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 920 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.6% of sh out |
| Days to cover14.7d |
| 13F net flow (QoQ)+1.10% |
| Top-10 13F concentration83.9% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$127.4M |
| Earnings (TTM)-$37.5M |
| ROE−612.1% |
| Net margin−30.0% |
| ROIC−10.7% |
| Debt / equity100.20× |
| Sales growth 3Y5.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−46.3% |
| 1Y−40.1% |
| 3Y−58.4% |
| Since incept. (ann.)−18.2% |
Total return through 2026-07-28 · series begins 2022-11-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)62.3% |
| Ann. volatility (3Y)68.4% |
| Sharpe (1Y)−0.51 |
| Sharpe (3Y)−0.05 |
| Max drawdown (1Y)−58.5% |
| Max drawdown (3Y)−66.2% |
| Beta (3Y vs SPY)1.27 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| 22NW, LP | 1,254 | $19M | 0.00% | +0.0% |
| WYNNEFIELD CAPITAL INC | 4.7M | $17M | 12.54% | +0.0% |
| Legion Partners Asset Management, LLC | 4.5M | $17M | 11.90% | +0.0% |
| Greenhaven Road Investment Management, L.P. | 3.5M | $13M | 9.43% | −3.9% |
| 325 CAPITAL LLC | 2.2M | $8M | 5.77% | +0.0% |
| BlackRock, Inc. | 1.9M | $7M | 5.00% | −1.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $5M | 3.44% | new |
| GRIZZLYROCK CAPITAL, LLC | 827,488 | $3M | 2.21% | +11.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$0.43 | — | $23.2M | — |
| 2025-09-30 | 2025-11-06 | −$0.29 | — | $31.1M | +25.9% |
| 2025-05-25 | 2025-08-07 | — | — | $40.5M | +6.9% |
| 2024-11-24 | 2025-01-02 | −$0.25 | −164.1% | $32.6M | +8.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
